Posted by Michael Wonder on 26 Mar 2025
Theratechnologies receives FDA approval for Egrifta WR (tesamorelin F8) to treat excess visceral abdominal fat in adults with HIV and lipodystrophy
25 March 2025 - New, improved formulation set to replace Egrifta SV.
Theratechnologies today announced that the US FDA has approved the Company’s supplemental biologics license application for the F8 formulation of tesamorelin for injection. The Company will commercialise the new formulation under the tradename Egrifta WR.
